ES2544808T3 - Miméticos sintéticos de LTA y uso de los mismos como componente de vacuna para la terapia y/o profilaxis de infecciones gram-positivas - Google Patents

Miméticos sintéticos de LTA y uso de los mismos como componente de vacuna para la terapia y/o profilaxis de infecciones gram-positivas Download PDF

Info

Publication number
ES2544808T3
ES2544808T3 ES11157947.0T ES11157947T ES2544808T3 ES 2544808 T3 ES2544808 T3 ES 2544808T3 ES 11157947 T ES11157947 T ES 11157947T ES 2544808 T3 ES2544808 T3 ES 2544808T3
Authority
ES
Spain
Prior art keywords
lta
prophylaxis
gram
therapy
vaccine component
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11157947.0T
Other languages
English (en)
Spanish (es)
Inventor
Johannes Huebner
Andrea Kropec-Huebner
Gijsbert Arie Van Der Marel
Wouter Frederik Johan HOGENDORF
Jeroen Dirk Cornelis CODÉE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitätsklinikum Freiburg
Leiden University
Original Assignee
Universitätsklinikum Freiburg
Leiden University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitätsklinikum Freiburg, Leiden University filed Critical Universitätsklinikum Freiburg
Application granted granted Critical
Publication of ES2544808T3 publication Critical patent/ES2544808T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/11—Esters of phosphoric acids with hydroxyalkyl compounds without further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES11157947.0T 2011-03-11 2011-03-11 Miméticos sintéticos de LTA y uso de los mismos como componente de vacuna para la terapia y/o profilaxis de infecciones gram-positivas Active ES2544808T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20110157947 EP2500349B1 (en) 2011-03-11 2011-03-11 Synthetic LTA mimetics and use thereof as vaccine component for therapy and/or prophylaxis against gram-positive infections

Publications (1)

Publication Number Publication Date
ES2544808T3 true ES2544808T3 (es) 2015-09-04

Family

ID=43828266

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11157947.0T Active ES2544808T3 (es) 2011-03-11 2011-03-11 Miméticos sintéticos de LTA y uso de los mismos como componente de vacuna para la terapia y/o profilaxis de infecciones gram-positivas

Country Status (6)

Country Link
US (1) US9290531B2 (enExample)
EP (1) EP2500349B1 (enExample)
JP (1) JP6154751B2 (enExample)
CA (1) CA2829126A1 (enExample)
ES (1) ES2544808T3 (enExample)
WO (1) WO2012119846A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013071409A1 (en) * 2011-11-18 2013-05-23 National Research Council Of Canada (Nrc) Clostridium difficile lipoteichoic acid and uses thereof
WO2018013999A1 (en) 2016-07-15 2018-01-18 Am Chemicals Llc Non-nucleosidic solid supports and phosphoramidite building blocks for oligonucleotide synthesis
KR101950881B1 (ko) * 2017-08-10 2019-02-22 서울대학교산학협력단 리포테이코익산(Lipoteichoic acid(LTA))을 함유하는 피부 재생 및 창상 치유용 약학 조성물
US11395849B2 (en) * 2017-09-07 2022-07-26 Merck Sharp & Dohme Llc Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0807185B9 (en) * 1995-01-30 2002-12-11 Lunamed AG Antitumor preparations containing a lipoteichoic acid from steptococcus
AUPQ137699A0 (en) 1999-07-02 1999-07-22 University Of New England, The Control of acidosis
AU2003203079B9 (en) * 2002-02-04 2009-01-15 Oncothyreon Inc. Immunostimulatory, covalently lipidated oligonucleotides

Also Published As

Publication number Publication date
EP2500349B1 (en) 2015-05-06
EP2500349A1 (en) 2012-09-19
JP2014507450A (ja) 2014-03-27
HK1175786A1 (en) 2013-07-12
WO2012119846A1 (en) 2012-09-13
CA2829126A1 (en) 2012-09-13
US9290531B2 (en) 2016-03-22
JP6154751B2 (ja) 2017-06-28
US20140050741A1 (en) 2014-02-20

Similar Documents

Publication Publication Date Title
AR076753A1 (es) Derivados de carboxamida y urea aromaticas sustituidas como ligandos del receptor de vanilloides.
Wahid et al. Live oral Salmonella enterica serovar Typhi vaccines Ty21a and CVD 909 induce opsonophagocytic functional antibodies in humans that cross-react with S. Paratyphi A and S. Paratyphi B
CO6260103A2 (es) Composiciones que comprenden antigenos neumococidos
DOP2009000124A (es) Derivados de benzamida como receptores agonista ep4
NI201200044A (es) Compuestos de dióxido de iminotiadiazina como inhibodores de bace , composiciones y su uso
CY1117097T1 (el) Ενωσεις ετεροαρυλο πυριδονης και αζα-πυριδονης ως αναστολεις της δρασης της βτκ
DOP2011000264A (es) Derivados de aminotetralina, composiciones farmaceuticas que los contienen y sus usos en terapia
PA8827901A1 (es) Derivados de quinoxalin- y quinolin-carboxamida
RU2017123262A (ru) Иммуногенные композиции для применения в пневмококковых вакцинах
MX2007009162A (es) Formas de dosis rsistente al alcohol.
CL2008003789A1 (es) Compuestos derivados de bencimidazol sustituido por carboxilo o por hidroxilo, moduladores selectivos del receptor x de farnesoide (fxr); proceso de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la diabetes, dislipidemia, sindrome metabolico, cancer, alzheimer.
UY32174A (es) Nuevos heterociclos sustituidos, composiciones farmaceuticas conteniendolos, procedimientos de preparacion y aplicaciones
NZ759686A (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
DOP2010000387A (es) Compuestos pirazolicos 436
UY32062A (es) Inhibidores de beta-secretasa
ECSP11010948A (es) Inhibidores de las enzimas de proteína cinasa activadas por
CO6390101A2 (es) Compuestos purina
ECSP078018A (es) Agonistas del receptor de niacina, composiciones que contienen tales compuestos y procedimientos para tratamiento
CR20120626A (es) Formulaciones farmacéuticas que comprenden derivados de 1-(beta- D-glucopiranosil)-2-tienilmetil]benceno como inhibidores de los transportadores de glucosa dependientes de sodio (SGLT)
MX2011012934A (es) Lipopolisacarido de ochrobactrum intermedium y su uso como inmunoestimulante en mamiferos.
AR069508A1 (es) Derivados de quinolina 057; un proceso para su preparacion; una composicion farmaceutica; la preparacion de esta y el uso del compuesto para preparar un medicamento
CU20120083A7 (es) Procedimiento para la preparación de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo y su purificación para el uso como principio activo farmacéutico
GT200600163A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
BR112016012306A2 (pt) peptídeos ricos em prolina para proteção contra s. pneumoniae
WO2016198170A8 (en) Vaccines against streptococcus pneumoniae serotype 5